Go Back to Match Results for ""

A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial
Study Overview
This randomized phase III trial studies how well aspirin works in preventing the cancer from coming back (recurrence) in patients with human epidermal growth factor receptor 2 (HER2) breast cancer after chemotherapy, surgery, and/or radiation therapy.
Study Description
The purpose of this study is to compare the effect of aspirin (300 mg daily) versus placebo upon invasive disease free survival (iDFS) in early stage node-positive HER2 negative breast cancer patients.
Additional Information
- IRB Number: 1701922942 (A011502)
- Research Study Identifier: TX7374
- Principal Investigator: Kathy Miller, MD
Recruitment Status
OpenContact the research team to learn more about this study.
Fields marked with asterisk (*) are required